Last reviewed · How we verify
Conversion schedule - Week 2
The drug, currently marketed by St. Joseph's Hospital and Medical Center, Phoenix, faces a key composition patent expiry in 2028. Its primary strength lies in its established market presence, leveraging the hospital's reputation and existing patient base. The primary risk is the potential increase in competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Conversion schedule - Week 2 |
|---|---|
| Also known as | clobazam (Onfi) |
| Sponsor | St. Joseph's Hospital and Medical Center, Phoenix |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma (PHASE2)
- Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） (PHASE2)
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study (PHASE4)
- Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants (PHASE3)
- Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants (PHASE3)
- Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC (PHASE1, PHASE2)
- Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease (PHASE4)
- Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: